Abstract:Unlike many other diagnostic tests, a negative exome sequencing does not rule out a genetic disorder; instead, it only implies that a genetic diagnosis could not be identified, given the clinical and genetic information available at the time of analysis. Reanalyzing exome data from unsolved cohorts with neurodevelopmental disorders (NDD) holds significant importance for several reasons [1]. Firstly, it allows for the identification of potentially missed or misclassified genetic variants. The initial analysis of exome data may have been limited by the available knowledge at the time, as well as the algorithms and filtering strategies employed. Revisiting the data with improved variant calling algorithms and updated databases can unmask previously concealed genomic variations and lead to the discovery of disease-causing variants that were initially overlooked. Secondly, the reanalysis provides an opportunity to evaluate diagnostic variants according to current standards and guidelines [2]. Over time, our understanding of variant pathogenicity and gene-disease associations evolves, necessitating a reassessment of previously reported variants. By applying updated classification criteria and incorporating additional evidence, such as functional studies or confirmatory publications, the pathogenicity of variants can be more accurately determined. Furthermore, reanalyzing exome data allows for the confirmation or removal of gene-disease associations (GDA). As new research emerges, some previously reported associations may be called into question or require further validation. By critically evaluating the evidence supporting the GDAs, we refine our understanding of the genetic basis of NDD and establish more reliable genotype-phenotype correlations. Lastly, reanalysis can uncover previously unknown gene associations. The constantly expanding knowledge base of gene-disease relationships, with hundreds of new associations being identified each year, provides a valuable resource for revisiting unsolved cohorts. By leveraging this wealth of information and employing advanced computational tools and filtering strategies, researchers can identify novel gene candidates and establish their role in NDD.

Increase in Diagnostic Yield Achieved for 174 Whole-Exome Sequencing Cases Reanalyzed 1-2 Years after Initial Analysis.

Increased Diagnostic Yield by Reanalysis of Whole Exome Sequencing Data in Mitochondrial Disease

Reanalysis of Whole Exome Sequencing Data in Patients with Epilepsy and Intellectual Disability/mental Retardation

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Clinical application of whole-exome sequencing across clinical indications

Marked Yield of Re-Evaluating Phenotype and Exome/target Sequencing Data in 33 Individuals with Intellectual Disabilities

Increased diagnostic yield by reanalysis of data from a hearing loss gene panel

Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data

The application of whole-exome sequencing in the early diagnosis of rare genetic diseases in children: a study from Southeastern China

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Exome and Whole-Genome Sequencing As Clinical Tests: a Transformative Practice in Molecular Diagnostics.

Long-read genome sequencing and variant reanalysis increase diagnostic yield in neurodevelopmental disorders

Long-read sequencing identified a causal structural variant in an exome-negative case and enabled preimplantation genetic diagnosis

Case report: Early use of whole exome sequencing unveils HNRNPU-related neurodevelopmental disorder and answers additional clinical questions through reanalysis

Application of whole exome sequencing in carrier screening for high-risk families without probands

Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities

Prenatal diagnosis of fetuses with ultrasound anomalies by whole-exome sequencing in Luoyang city, China

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Unveiling the hidden: revisiting the potential of old genetic data for rare disease research

Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis